Amarin | AMRN - Koszty Sprzedaży





Koszty Sprzedaży Zmiana Data
AbbVie USD 4.55B 757M 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amarin USD 16.89M 18.51M 2025-03
AstraZeneca USD 3.27B 471M 2025-12
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Esperion Therapeutics USD 27.85M 13.43M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.54B 217M 2025-09